Çѱ¹¹ÙÀÌ¿ÀÀǾàÇ°Çùȸ ´º½º·¹ÅÍ ±¹¹® Å×½ºÆ®ÆÄÀÏ
|
|
|
ÇàÁ¤¿¹°í |
¡¸Èñ±ÍÀǾàÇ° ÁöÁ¤¿¡ °üÇÑ ±ÔÁ¤¡¹ÀϺΰ³Á¤°í½Ã(¾È) ÇàÁ¤¿¹°í
´º½Ã³Ê¼¾(ÁÖ»çÁ¦) µî 2°³ ¼ººÐÀ» Èñ±ÍÀǾàÇ°À¸·Î ½Å±Ô ÁöÁ¤ÇÔ......´õ º¸±â
¡Ø ´º½Ã³Ê¼¾ : ô¼ö¼º ±ÙÀ§ÃàÁõ Ä¡·áÁ¦, »ýÁ¸¿îµ¿½Å°æ¿ø(SMN) ´Ü¹éÁú »ý»êÀ» Áõ°¡½ÃÅ°±â À§ÇØ SMN2 À¯ÀüÀÚ¿¡¼ Àü·É RNA Àü±¸Ã¼ÀÇ ½ºÇöóÀ̽ÌÀ» º¯È½ÃÅ°µµ·Ï ¸¸µé¾îÁø ¾ÈƼ¼¾½º ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ¾à¹°
|
|
¹ßÇ¥ÀÚ·á |
2017³â ±¹Á¦ÀǾàÇ°±ÔÁ¦Á¶ÈÀ§¿øȸ (ICH) »ê°ü ÇÕµ¿ ¼³¸íȸ ÀÚ·á
2017³â ±¹Á¦ÀǾàÇ°±ÔÁ¦Á¶ÈÀ§¿øȸ(ICH) »ê°ü ÇÕµ¿ ¼³¸íȸ ¹ßÇ¥ÀڷḦ °Ô½ÃÇÕ´Ï´Ù.
¡Û ÀϽà : 2017³â 7¿ù 5ÀÏ(¼ö)
¡Û Àå¼Ò : ¼¿ï ÄÚ¿¢½º EȦ
¡Û ¹ßÇ¥ÀÚ·á
- ±¹Á¦ÀǾàÇ°±ÔÁ¦ÀÚÆ÷·³(IPRF)/±¹Á¦ÀǾàÇ°±ÔÁ¦Á¶ÈÀ§¿øȸ(ICH) ȸÀÇ °á°ú
- ICH °¡À̵å¶óÀÎ °øµ¿°³¹ß ÇöȲ
- ´ÙÁö¿ªÀÓ»ó½ÃÇè °¡À̵å¶óÀÎ......´õ º¸±â |
|
|
º¸µµÀÚ·á |
½Ä¾àó, ±¹³» °³¹ß ÃÖÃÊ À¯ÀüÀÚÄ¡·áÁ¦ ¡®Àκ¸»çÄÉÀÌÁÖ¡¯ Çã°¡
¡à ½ÄÇ°ÀǾàÇ°¾ÈÀüó(óÀå ¼Õ¹®±â)´Â ¹«¸ °ñ°üÀý¿° Ä¡·áÁ¦·Î ±¹³»¿¡¼ óÀ½ °³¹ßµÈ À¯ÀüÀÚÄ¡·áÁ¦ ½Å¾à ¡®Àκ¸»çÄÉÀÌÁÖ¡¯¸¦ 7¿ù 12ÀÏ Çã°¡ÇÑ´Ù°í ¹àÇû´Ù.
¡Ø À¯ÀüÀÚÄ¡·áÁ¦: À¯Àü¹°Áú ¹ßÇö¿¡ ¿µÇâÀ» ÁÖ±â À§ÇÏ¿© Åõ¿©ÇÏ´Â À¯Àü¹°Áú ¶Ç´Â À¯Àü¹°ÁúÀÌ º¯ÇüµÇ°Å³ª µµÀÔµÈ ¼¼Æ÷¸¦ ÇÔÀ¯ÇÏ°í ÀÖ´Â ÀǾàÇ°
¡Û À̹ø¿¡ Çã°¡µÈ À¯ÀüÀÚÄ¡·áÁ¦´Â Ç׿°Áõ ÀÛ¿ëÀ» ³ªÅ¸³»´Â ¡®TGF-¥â1 À¯ÀüÀÚ¡¯°¡ µµÀÔµÈ µ¿Á¾¿¬°ñÀ¯·¡¿¬°ñ¼¼Æ÷¸¦ ÁÖ¼ººÐÀ¸·Î Çϸç, ±¹³» ½Å¾àÀ¸·Î´Â 29¹ø°´Ù.
¡Ø TGF-¥â1: ¿°Áõ¾ïÁ¦, »óó Ä¡À¯ µî¿¡ ÀÛ¿ëÇÏ´Â ´Ü¹éÁúÀÇ ÀÏÁ¾
¡Û ÇöÀç±îÁö ¹Ì±¹, À¯·´ µî ÁÖ¿ä Á¦¾à¼±Áø±¹ÀÌ Çã°¡ÇÑ À¯ÀüÀÚÄ¡·áÁ¦´Â 4°³ Ç°¸ñÀ¸·Î ¸é¿ª°áÇÌÁúȯ, À¯ÀüÁúȯÀ̳ª Ç×¾ÏÄ¡·á¸¦ ¸ñÀûÀ¸·Î »ç¿ëµÇ¸ç, ÅðÇ༺ ÁúȯÀÎ ¹«¸ °ñ°üÀý¿° Ä¡·á¸¦ À§ÇÑ À¯ÀüÀÚÄ¡·áÁ¦´Â Àκ¸»çÄÉÀÌÁÖ°¡ óÀ½ÀÌ´Ù.
¡à ½Ä¾àó´Â Àκ¸»çÄÉÀÌÁÖ¸¦ Çã°¡¡¤½É»çÇÏ´Â ´Ü°è¿¡¼ ¡ãÇØ´çÁ¦Ç° Åõ¿© ÈÄ ÅëÁõ°ú °üÀý±â´É °³¼± Á¤µµ ¡ã¿¬°ñ ±¸Á¶ °³¼± È¿°ú ¡ãÁ¦Ç° Åõ¿© ÈÄ ¹ß»ýÇÏ´Â ÀÌ»ó¹ÝÀÀ ¡ãÁ¦Ç° Åõ¿© ÈÄ Àå±âÃßÀûÁ¶»ç¸¦ ÅëÇØ µÚ´Ê°Ô ³ªÅ¸³ª´Â ÀÌ»ó¹ÝÀÀ µî ÀڷḦ ÁßÁ¡ÀûÀ¸·Î °ËÅäÇÏ¿´À¸¸ç, Áß¾Ó¾à»ç½ÉÀÇÀ§¿øȸÀÇ ÀÚ¹®À» °ÅÃÄ ÃÖÁ¾ Çã°¡¸¦ °áÁ¤ÇÏ¿´´Ù.
¡à ½Ä¾àó´Â Áö³ ¡®14³âºÎÅÍ ¹ÙÀÌ¿À¾÷üÀÇ °³¹ßÀ» Áö¿øÇϱâ À§ÇÏ¿© ¡®¸¶Áß¹°»ç¾÷¡¯À» ¿î¿µÇÏ°í ÀÖÀ¸¸ç, À̹ø À¯ÀüÀÚÄ¡·áÁ¦µµ ¡®¸¶Áß¹°»ç¾÷¡¯À» ÅëÇØ Ç°Áú°ü¸® ±âÁØ ¼³Á¤ µî¿¡ ´ëÇÑ ¹ÐÂø»ó´ãÀ» ¹Þ¾Æ °³¹ß °úÁ¤ Áß ½ÃÇàÂø¿À¸¦ ÃÖ¼ÒÈ ÇÒ ¼ö ÀÖ¾ú´Ù°í ¹àÇû´Ù........ ´õ º¸±â
|
|
¼ö¿äÁ¶»ç |
¡¸ÀǾàÇ° ÁÖ¿ä¼öÃâ±¹ ±ÔÁ¦´ç±¹ÀÚ ÃÊû ¿öÅ©¼ó¡¹¹× ¡¸ÀÏ´ëÀÏ(1:1) ¸ÂÃãÇü »ó´ã¡¹°³ÃÖ ¼ö¿ä Á¶»ç(~7¿ù 21±îÁö)
½ÄÇ°ÀǾàÇ°¾ÈÀüÆò°¡¿ø ¾àÈ¿µ¿µî¼º°ú¿¡¼´Â ÁÖ¿ä ¼öÃâ±¹ÀÎ ·¯½Ã¾Æ, ÅÍÅ°, ¿ìÁŰ½ºÅº 3°³±¹ ÀǾàÇ° ±ÔÁ¦±â°ü °ü¸®ÀÚ±ÞÀ» ÃÊûÇÏ¿© 8¿ù 23ÀÏ, ¼¿ï(ÄÚ¿¢½º)¿¡¼ Á¦¾à¾÷°è ´ë»ó ¿öÅ©¼óÀ» °³ÃÖÇÏ°í ÀÏ´ëÀÏ(1:1) ¸ÂÃãÇü »ó´ãÀ» ½Ç½ÃÇÒ ¿¹Á¤ÀÔ´Ï´Ù.
¡Ø Âü¿© È®Á¤ ¾÷ü ´ë»ó »çÀü °£´ãȸ ('17.7.27 ½Ç½Ã ¿¹Á¤)
¡Û À̹ø ¿öÅ©¼óÀº ·¯½Ã¾Æ, ÅÍÅ°, ¿ìÁŰ½ºÅº ÀǾàÇ° Çã°¡´ã´ç ±ÔÁ¦´ç±¹ÀÚ¸¦ ÃÊûÇÏ¿© °¢ ±¹°¡ÀÇ ÀǾàÇ° Çã°¡½É»ç Á¦µµ¿¡ °üÇÑ Á¤º¸¸¦ Á¦°øÇÔÀ¸·Î½á ÇØ´ç ±¹°¡¿¡ ´ëÇÑ ÀǾàÇ°ÀÇ ¼öÃâÀ» Áö¿øÇϱâ À§ÇØ ¸¶·ÃµÇ¾ú½À´Ï´Ù.
¡Û ƯÈ÷, ±¹°¡º° ¸ÂÃãÇü »ó´ãÀ» ÅëÇØ ÀǾàÇ° ¼öÃâ½Ã ±Ã±ÝÇÑ Á¡°ú ¾Ö·Î »çÇ× µîÀ» Á÷Á¢ »ó´ã ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù.......´õ º¸±â |
|
|
|
|
º¹ÁöºÎ |
2017³â Å©·Î¾ÆƼ¾Æ ¹Î°ü ÇÕµ¿ º¸°ÇÀÇ·áÇù·Â »çÀý´Ü ÆÄ°ß ¼ö¿äÁ¶»ç (~7/27ÀϱîÁö)
¡Û ÀÏÁ¤ : 2017³â 10¿ù¸», 3¹Ú4ÀÏ (ÀáÁ¤¾È) *»çÀý´Ü ÆÄ°ß ¿©ºÎ¿¡ µû¶ó Çà»ç °³ÃÖ ÀÏÁ¤ º¯°æ°¡´É
¡Û ¹æ¹®±¹°¡ : Å©·Î¾ÆƼ¾Æ(ÀÚ±×·¹ºê)
¡Û ÁÖ¿äÈ°µ¿
- ¾ç±¹ º¸°ÇºÎ°£ º¸°ÇÇù·Â MOU ü°á
- Á¤ºÎ ÁÖ¿äÀÎ»ç ¸é´ã
- ÇöÀå½ÃÂû, 1:1 ºñÁî´Ï½º »ó´ãȸ
- ÇÑ-Å©·Î¾ÆƼ¾Æ Á¦¾à ÀÇ·á±â±â ¼¼¹Ì³ª °³ÃÖ µî
¡Û ´ëÇ¥´Ü ±¸¼º : º¸°Çº¹ÁöºÎ, °ü°èºÎó, Çѱ¹º¸°Ç»ê¾÷ÁøÈï¿ø, °ø°ø±â°ü, Á¦¾à ÀÇ·á±â±â °ü°è±â¾÷ ¹× Çùȸ µî
¡Û Çù·Â±â°ü : Àç¿Ü°ø°ü, Çѱ¹º¸°Ç»ê¾÷ÁøÈï¿ø, Çѱ¹¹«¿ªÅõÀÚÁøÈï°ø»ç(KOTRA)......´õ º¸±â
|
|
|
|
|
|
½ÅûÀÚ |
½ÂÀÎÀÏ |
Á¦Ç°¸í |
ÀÓ»ó |
´Ü°è |
(ÁÖ)¼¿Æ®¸®¿Â |
20170717 |
°Ç°ÇÑ ¼ºÀÎ ³²¼º ½ÃÇè´ë»óÀÚ¿¡¼ º£¹Ù½ÃÁÖ¸¿ 3°¡Áö Á¦Á¦(CT-P16, À¯·´¿¬ÇÕ ½ÂÀÎ ¾Æ¹Ù½ºÆ¾, ¹Ì±¹ Çã°¡ ¾Æ¹Ù½ºÆ¾)ÀÇ ¾àµ¿Çаú ¾ÈÀü¼ºÀ» ºñ±³ÇÏ´Â ¹«ÀÛÀ§¹èÁ¤, ÀÌÁß´«°¡¸², 3°³±º, ÆòÇ౺, ´ÜȸÅõ¿© ½ÃÇè
|
1»ó |
CT-P16 |
ÄھƽºÅÛ(ÁÖ) |
20170717 |
·çǪ½º ½Å¿° ȯÀÚ¿¡¼ CS20AT04 ÁÖÀÇ 1»ó ÀÓ»ó½ÃÇè(CS20AT04-LN101)¿¡ Âü¿©ÇÏ¿´´ø ´ë»óÀÚÀÇ ¾ÈÀü¼º Àå±â ÃßÀû °üÂû |
¿¬Àå |
CS20AT04 |
ÄýŸÀÏÁîÆ®·£½º³»¼Å³ÎÄÚ¸®¾Æ(ÁÖ) |
20170717 |
´çÁúÄÚ¸£Æ¼ÄÚÀ̵å À¯µµ¼º °ñ´Ù°øÁõÀÌ ÀÖ´Â ¼Ò¾Æ ½ÃÇè´ë»óÀÚ¿¡¼ µ¥³ë¼ö¸¿ÀÇ ¾ÈÀü¼º ¹× À¯È¿¼ºÀ» Æò°¡Çϱâ À§ÇÑ Á¦ 3»ó ¹«ÀÛÀ§¹èÁ¤, ÀÌÁß ´«°¡¸², À§¾à ´ëÁ¶, ÆòÇ౺ ½ÃÇè |
3»ó |
µ¥³ë¼ö¸¿
(Denosumab) |
Çѱ¹¿¥¿¡½ºµð(À¯) |
20170714 |
ÁøÇ༺ °íÇü¾Ï ȯÀÚ¸¦ ´ë»óÀ¸·Î ´Üµ¶¿ä¹ýÀ¸·Î ±×¸®°í Pembrolizumab°úÀÇ º´¿ë¿ä¹ýÀ¸·Î Åõ¿©ÇÑ MK-7684¸¦ Æò°¡ÇÏ´Â Á¦1»ó ÀÓ»ó½ÃÇè |
1»ó |
1. MK-8353,
2. Pembrolizumab |
(À¯)Çѱ¹ºñ¿¥¿¡½ºÁ¦¾à |
20170713 |
Ãʱ⠺´±âÀÇ ºñ¼Ò¼¼Æ÷¾Ï(NSCLC)¿¡¼ ´Ïº¼·ç¸¿°ú ÀÌÇʸ®¹«¸¿À» ¹é±Ý- 2 Á¦ Ç×¾ÏÈÇпä¹ý°ú ºñ±³ÇÏ´Â ¹«ÀÛÀ§ ¹èÁ¤, °ø°³, Á¦3»ó ½ÃÇè |
3»ó |
NivolumabÁÖ |
(ÁÖ)¾ËÅ׿ÀÁ¨ |
20170711 |
¼ºÀÎ ¼ºÀåÈ£¸£¸ó°áÇÌÁõ(AGHD) ȯÀÚ¸¦ ´ë»óÀ¸·Î ALT-P1(ÀçÁ¶ÇÕ Áö¼ÓÇü Àΰ£ ¼ºÀåÈ£¸£¸ó) 4ÁÖ Åõ¿© ÈÄ, ¾àµ¿ÇÐ/¾à·ÂÇÐ ¹× ¾ÈÀü¼º Æò°¡¸¦ À§ÇÑ °ø°³, ´ÜÀϱº, º´Çà, ´Ù±â°ü Á¦1b/2a»ó ÀÓ»ó½ÃÇè
|
1/2a»ó |
ALT-P1 |
|
|
|
|
|
|
|
|
FDA |
|
Drug Name and
FDA Appl. # |
Active Ingredients |
Submission
Classification |
Company |
Approval Date |
TREMFYA
BLA #761061 |
GUSELKUMAB |
- |
JANSSEN BIOTECH |
07/13/2017 |
ZYPITAMAG
NDA #208379 |
PITAVASTATIN |
Labeling |
ZYDUS PHARMS USA INC |
07/14/2017 |
NERLYNX
NDA #208051 |
NERATINIB MALEATE |
Labeling |
PUMA BIOTECH INC |
07/17/2017 |
|
|
|
|
EMA |
|
Name |
Active Substance |
Therapeutic areaCompany |
Date of authorisation/ refusal |
Skilarence |
dimethyl fumarate |
Psoriasis |
23/06/2017 |
Besponsa |
inotuzumab ozogamicin |
Precursor Cell Lymphoblastic
Leukemia-Lymphoma |
29/06/2017 |
|
|
|
|
|
|
|
|
Clinical.gov ¹Ì±¹ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03217747 |
Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies |
- Malignant Neoplasm of Breast
-
Malignant Neoplasms of Bone and Articular Cartilage
- Malignant Neoplasms of Digestive Organs
-
Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System
-
Malignant Neoplasms of Female Genital Organs ... |
Drug: Avelumab
Drug: Utomilumab
Drug: PF-04518600
Radiation: Radiation
Drug: Cisplatin |
- M.D. Anderson
Cancer Center
- Pfizer |
Phase 1
Phase 2 |
NCT03219359 |
Autologous Stem Cell Transplant for Crohn's Disease |
Crohn Disease |
Procedure: Autologous stem cell transplant
Drug: Vedolizumab
Drug: Cyclophosphamide
Drug: Cyclophosphamide
Drug: Thymoglobulin
Drug: Methylprednisolone |
Icahn School of Medicine at Mount Sinai |
Phase 2 |
NCT03215810 |
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer |
Non Small Cell Lung Cancer |
Procedure: Tumor-infiltrating Lymphocytes
Drug: Nivolumab
Drug: Cyclophosphamide
Drug: Fludarabine
Other: Tumor-infiltrating
Lymphocyte Therapy
Drug: Interleukin-2 |
- H. Lee Moffitt Cancer Center and Research Institute
- Bristol-Myers Squibb
Prometheus Inc.
- Stand Up To Cancer |
Phase 1 |
NCT03219268 |
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms |
- Advanced Solid Tumors
- Non-small Cell Lung Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Small Cell Lung Cancer
-
Diffuse Large B Cell Lymphoma
-
Epithelial Ovarian Cancer |
Biological: MGD013 |
MacroGenics |
Phase 1 |
NCT03217734 |
MAP Study: Methotrexate and Adalimumab in Psoriasis |
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic|Non-Hodgkin Lymphoma |
Biological: Adalimumab |
- Jeffrey J Crowley MD
- AbbVie
- Bakersfield Dermatology &
Skin Cancer Medical Group |
Phase 2
Phase 3 |
|
|
Clinical.gov À¯·´ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
Nation |
NCT03217643 |
CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1. |
Enteropathy Associated T-cell Lymphoma |
Drug: Brentuximab Vedotin |
Imagine Institute |
Phase 2 |
ÇÁ¶û½º |
NCT03215706 |
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) |
Non-Small Cell Lung Cancer |
Biological: Ipilimumab
Biological: Nivolumab
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Cisplatin |
Bristol-Myers Squibb |
Phase 3 |
µ¶ÀÏ |
|
|
Clinical.gov Áß±¹ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03217812 |
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy
(Asia Pacific Region) |
Multiple Myeloma
|
Drug: Velcade
Drug: Melphalan
Drug: Prednisone
Drug: Daratumumab |
Janssen Research & Development, LLC |
Phase 3 |
|
|
|
|
|
|
¹ÙÀÌ¿ÀITÇ÷§Æû '17³â ½Å±ÔÁ¦°øÁ¤º¸ ¾È³» |
¹ÙÀÌ¿ÀITÇ÷§ÆûÀÇ 2017³â ½Å±Ô Á¦°ø Á¤º¸ |
2017³âµµ¿¡´Â Áö³ ÇØ ±ÔÁ¦¡¤»ê¾÷Á¤º¸¸¦ Á¦°øÇÏ¿´´ø 12°³±¹ ¿Ü¿¡ º£Æ®³², Àεµ³×½Ã¾Æ, ÆÄÅ°½ºÅºÀÇ 3°³±¹ Á¤º¸¸¦ Ãß°¡·Î Á¦°øÇÒ ¿¹Á¤ÀÔ´Ï´Ù. ¸¹Àº °ü½É°ú ÀÌ¿ëÀ» ºÎŹ µå¸³´Ï´Ù. |
|
¹ÙÀÌ¿ÀITÇ÷§Æû Àü¹®ÄÁ¼³Æà ¾È³» |
2017³â¿¡´Â ÁÖ¿ä ±Ç¿ª(¹Ì±¹, À¯·´, Áß±¹)º° Àü¹® ÄÁ¼³Æà ¾÷üÀÇ ÀÎÇã°¡ Á¾ÇÕ Áö¿ø ¼ºñ½º(2017 ÷´Ü¹ÙÀÌ¿ÀÀǾàÇ° ÇØ¿ÜÁøÃâ Á¾ÇÕÁö¿ø »ç¾÷ ¡º¹ÙÀÌ¿ÀITÇ÷§Æû¡» Àü¹®ÄÁ¼³ÆÃ)¸¦ »õ·Ó°Ô ½Ç½ÃÇÒ ¿¹Á¤ÀÔ´Ï´Ù. ¸¹Àº ½Åû ¹Ù¶ø´Ï´Ù. |
'Àü¹®ÄÁ¼³ÆÃ' À̶õ? |
¹ÙÀÌ¿ÀÀǾàÇ° ÇØ¿Ü ÀÎÇã°¡ °ü·Ã ¾÷¹«°æÇèÀÌ ÀÖ´Â Àü¹® ÄÁ¼³Æà ±â°üÀÇ
1:1(ÄÁ¼³Æñâ°ü:ÄÁ¼³Æà ÀÇ·Ú ¾÷ü) ÄÁ¼³Æà |
|
|
Èñ¸ÁÇϽô ¾÷ü²²¼´Â Çùȸ ¶Ç´Â ¹ÙÀÌ¿ÀITÇ÷§Æû ȨÆäÀÌÁöÀÇ ¡®¹ÙÀÌ¿ÀITÇ÷§Æû Àü¹®ÄÁ¼³Æà ½Åû¡¤Á¢¼ö °ø°í¡¯¸¦ È®ÀÎÇϽðí,
¡®¹ÙÀÌ¿ÀÀǾàÇ° ÇØ¿ÜÁøÃâ Àü¹®ÄÁ¼³Æà ÀÇ·Ú¼¡¯¸¦ ÀÛ¼ºÇϽþî À̸ÞÀÏ(bpis@kobia.kr) ½Åû¡¤Á¢¼öÇϽñ⠹ٶø´Ï´Ù.
µ¿ÀÏ ±â¾÷Àº ÃÖ´ë 5°Ç±îÁö ½ÉÈ, ¿¬°è ÄÁ¼³ÆÃ(´Ü°èº°) ÀÇ·Ú°¡ °¡´ÉÇÕ´Ï´Ù. |
|
¢º ¹ÙÀÌ¿ÀITÇ÷§Æû Àü¹®ÄÁ¼³Æà °ø°í (»ó½ÃÁ¢¼ö) ¹Ù·Î°¡±â |
|
¢º ¹ÙÀÌ¿ÀITÇ÷§Æû ¹Ù·Î°¡±â |
|
|
|
|
|
|
|
|
|
|
|
|
|
|